On May 02, 2014, Oncomed Pharmaceuticals Inc (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that the U.S. Food and Drug Administration (FDA) Department of Orphan Products Development has granted orphan drug designation to demcizumab (anti-DLL4, OMP-21M18) for the treatment of pancreatic cancer. Oncomed Pharmaceuticals Inc (NASDAQ:OMED), shares after opening at $26.76 moved to $27.51 on last trade day and at the end of the day closed at $24.95. Company price to sales ratio in past twelve months was calculated as 19.50 and price to cash ratio as 2.33. Oncomed Pharmaceuticals Inc (NASDAQ:OMED), showed a negative weekly performance of 5.28%.
NanoString Technologies Inc (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, reported financial results for the three months ended March 31, 2014. NanoString Technologies Inc (NASDAQ:NSTG), shares fell 13.21% in last trading session and ended the day on $14.26. NanoString Technologies Inc (NASDAQ:NSTG), return on equity ratio is recorded as 95.70% and its return on assets is -69.30%.
TG Therapeutics, Inc. (NASDAQ:TGTX), will participate in the 39th Annual Deutsche Bank Healthcare Conference being held at The InterContinental in Boston, MA. Michael S. Weiss, the Company’s Executive Chairman and Interim Chief Executive Officer, will be participating in a question and answer session on Thursday May 8, 2014 at 12:50 PM ET. TG Therapeutics, Inc. (NASDAQ:TGTX), shares moved down 9.53% in last trading session and was closed at $4.84, while trading in range of $ 4.76 – 5.51. TG Therapeutics, Inc. (NASDAQ:TGTX), year to date (YTD) performance is 24.10%.
GenVec Inc (NASDAQ:GNVC), reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012. GenVec ended the year with $6.1 million in cash, cash equivalents, and short-term investments. GenVec Inc (NASDAQ:GNVC), weekly performance is -6.85%. On last trading day company shares ended up $2.31. GenVec Inc (NASDAQ:GNVC), distance from 50-day simple moving average (SMA50) is -19.81%. Analysts mean target Price for the company is $8.50.
Leave a Reply